Andrew J. Hale, MD

home / authors / andrew-j-hale-md

Andrew J. Hale, MD, is an infectious disease physician at the University of Vermont Medical Center and an assistant professor of medicine at Larner College of Medicine at the University of Vermont in Burlington.

Articles

Reduced-Dose Trimethoprim-Sulfamethoxazole Effective in Treating Mild to Moderate Pneumocystis jirovecii Pneumonia

Kyle Crooker, MD;Eleanor Stedman, MD;Sean S. M. Bullis, MD;Andrew J. Hale, MD

September 20th 2022

Here is a review of using this therapy in this patient population.

Is There a Better Choice Than TMP-SMX to Treat Stenotrophomonas maltophilia Infections?

Kyle Crooker, MD;Sean S. M. Bullis, MD;Andrew J. Hale, MD

December 16th 2021

Mono or Combo? Exploring the Role of Combination Antimicrobial Therapies for Invasive Carbapenem-Resistant Gram-Negative Infections

Sean S. M. Bullis, MD;Andrew J. Hale, MD

August 17th 2021

Improving Vaccine Uptake in a Cohort of Patients With Asplenia

SEAN BULLIS, MD;Andrew J. Hale, MD

June 8th 2020

This is one of the first studies examining the effect of a dedicated postsplenectomy comprehensive clinic.

Where to Treat Uncomplicated HCV? Assessing the Impact of Shifting Care From Specialists to PCPs

SEAN BULLIS, MD;Andrew J. Hale, MD

October 8th 2019

One promising proposal to greatly increase access to DAA HCV therapy is to keep this treatment with appropriately trained PCPs, in contrast with referring patients to infectious disease, gastroenterology, or hepatology subspecialists.

Optimal Vancomycin Dosing in Obese Patients: Moving Toward the AUC

Andrew J. Hale, MD;Daniela Dimarco, MD;John W. Ahern, PharmD*

May 29th 2019

This In the Literature piece explores if we can mitigate some of the adverse reactions that are being seen in obese patients who receive vancomycin through AUC-dosing.